Princeton Global Asset Management’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.8K Hold
87
0.01% 375
2026
Q1
$48.9K Sell
87
-6
-6% -$3.85K 0.01% 357
2025
Q4
$62.9K Sell
93
-130
-58% -$88.5K 0.01% 319
2025
Q3
$142K Hold
223
0.02% 220
2025
Q2
$120K Buy
223
+6
+3% +$2.87K 0.02% 227
2025
Q1
$91.1K Hold
217
0.02% 235
2024
Q4
$89.7K Hold
217
0.02% 253
2024
Q3
$110K Hold
217
0.02% 231
2024
Q2
$106K Hold
217
0.02% 214
2024
Q1
$117K Hold
217
0.03% 192
2023
Q4
$120K Hold
217
0.03% 190
2023
Q3
$94.9K Hold
217
0.03% 198
2023
Q2
$109K Hold
217
0.03% 194
2023
Q1
$109K Buy
217
+87
+67% +$41.6K 0.03% 197
2022
Q4
$53K Hold
130
0.02% 234
2022
Q3
$42K Hold
130
0.01% 249
2022
Q2
$46K Hold
130
0.01% 259
2022
Q1
$71K Buy
+130
New +$68.4K 0.02% 233

Other funds holding IDXX

Princeton Global Asset Management's IDXX Position: Q2 2026 in Review

Princeton Global Asset Management held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 87 shares worth $45.8K. The position accounts for 0.01% of the portfolio, ranked #375.

Princeton Global Asset Management first reported a position in IDXX in Q1 2022 and has held it in 18 quarters since. The position peaked at $142K in Q3 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Princeton Global Asset Management held 87 shares of Idexx Laboratories worth $45.8K as of Q2 2026.
  • Princeton Global Asset Management left its Idexx Laboratories share count unchanged in Q2 2026.
  • Idexx Laboratories made up 0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #375 holding.
  • Princeton Global Asset Management first reported a position in Idexx Laboratories in Q1 2022 and has held it in 18 quarters since.
  • Princeton Global Asset Management's Idexx Laboratories position peaked at $142K in Q3 2025.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.